Autocrine IL-6 mediates pituitary tumor senescence

Oncotarget. 2017 Jan 17;8(3):4690-4702. doi: 10.18632/oncotarget.13577.

Abstract

Cellular senescence is a stable proliferative arrest state. Pituitary adenomas are frequent and mostly benign, but the mechanism for this remains unknown. IL-6 is involved in pituitary tumor progression and is produced by the tumoral cells. In a cell autonomous fashion, IL-6 participates in oncogene-induced senescence in transduced human melanocytes. Here we prove that autocrine IL-6 participates in pituitary tumor senescence. Endogenous IL-6 inhibition in somatotroph MtT/S shRNA stable clones results in decreased SA-β-gal activity and p16INK4a but increased pRb, proliferation and invasion. Nude mice injected with IL-6 silenced clones develop tumors contrary to MtT/S wild type that do not, demonstrating that clones that escape senescence are capable of becoming tumorigenic. When endogenous IL-6 is silenced, cell cultures derived from positive SA-β-gal human tumor samples decrease the expression of the senescence marker. Our results establish that IL-6 contributes to maintain senescence by its autocrine action, providing a natural model of IL-6 mediated benign adenoma senescence.

Keywords: IL-6; autocrine; benign tumor; pituitary tumor; senescence.

MeSH terms

  • Animals
  • Autocrine Communication*
  • Cell Line, Tumor
  • Cell Proliferation
  • Cellular Senescence
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • Humans
  • Interleukin-6 / genetics*
  • Interleukin-6 / metabolism*
  • Mice
  • Mice, Nude
  • Neoplasm Invasiveness
  • Neoplasm Transplantation
  • Phosphorylation
  • Pituitary Neoplasms / genetics
  • Pituitary Neoplasms / metabolism*
  • Pituitary Neoplasms / pathology
  • Retinoblastoma Protein / metabolism
  • beta-Galactosidase / metabolism

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • IL6 protein, human
  • Interleukin-6
  • Retinoblastoma Protein
  • beta-Galactosidase